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Abstract 
Objective: The goals of the interdisciplinary laboratory were to educate and engage pharmacy and physician assistant (PA) students 
in a discussion focused on the collection, interpretation, and application of pharmacogenetic data.  Design: Interdisciplinary teams 
participated in a one-hour, case-based discussion and provided a therapeutic recommendation using the Clinical Pharmacogenetics 
Implementation Consortium guidelines.  Assessment:  All students were surveyed before and after the laboratory on knowledge and 
application of pharmacogenetics and working in interdisciplinary teams.  The interdisciplinary laboratory successfully enhanced the 
student’s knowledge about sample collection and interpretation of pharmacogenetic information.  Additionally, the laboratory 
improved student confidence in working in interdisciplinary teams to apply pharmacogenetic information to clinical decision making.  
Furthermore, the majority of students indicated that the interdisciplinary laboratory is valuable and useful in healthcare curriculums.  
Conclusion: The laboratory highlighted the differences between pharmacy and PA education regarding PGt, and brought to light 
several important uncertainties: (1) What is the depth of PGt knowledge that healthcare practitioners need? (2) What are best 
practices for conveying PGt information?   
 
 
Description of Case 
Pharmacogenetics (PGt), the study of an individual’s drug 
response as it relates to a single gene, is changing therapeutic 
decision making.1  The acceptance of PGt into clinical practice 
necessitates the education of all healthcare providers in 
genetics and particularly PGt (or pharmacogenomics (PGx), 
the study of drug response as it relates to multiple genes).  In 
fact, the Accreditation Council for Pharmacy Education (ACPE) 
Standards 2016 will require all colleges of pharmacy to include 
PGx/PGt subject matter in the doctorate of pharmacy 
(Pharm.D.) curriculum.2  Just as pharmacists have historically 
been the drug-drug interaction experts among an 
interprofessional healthcare team, pharmacists will become 
the drug-gene interaction experts.  Therefore, an 
interdisciplinary education (IPE) experience that is focused in 
PGt provides pharmacy students a meaningful opportunity for 
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In choosing another discipline for the laboratory, the logical 
choice was a healthcare provider that can prescribe medicine.  
We partnered with a neighboring school that offers a 
physician assistants (PA) program to recruit PA students for 
the IPE laboratory.  The standards governing PA education 
dictate that basic pharmacology and genetic mechanisms 
must be included in the curriculum, but do not include specific 
requirements on PGt/PGx.3 For several of the PA students, the 
IPE laboratory was the first introduction to PGt.  In 
purposefully partnering pharmacy and PA students, the 
responsibilities of each discipline could be emphasized.4, 5  For 
instance, pharmacy students should interpret PGt findings, 
utilize the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) guidelines to recommend therapeutic 
choices, and explain the rationale for any recommendations 
to the PA students.  Similarly, the PA students should engage 
the pharmacy students in a discussion about the CPIC 
guidelines and gather enough concise information to share 
with their patients.  As a whole, the field of PGt will rely on 
interdisciplinary teams for implementation in patient care 
settings and this laboratory was focused on providing 
students that experience. 
 
The goals of the IPE laboratory were to educate, as well as, 
engage pharmacy and PA students in a discussion focused in 
the collection, interpretation, and application of PGt data.   
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To measure student perceptions about PGt/PGx, the 
pharmacy and PA students were surveyed before and after 
the IPE laboratory experience.  The themes, design and 
implications of this innovative IPE laboratory are discussed.  At 
the time of this publication and to the best of the authors’ 
knowledge, this is the first laboratory of its kind in healthcare 
education.   
 
Rationale and Design 
The IPE laboratory was housed within the Manchester 
University College of Pharmacy, Natural and Health Sciences 
Pharmacy Program.  Several key elements were considered 
when placing the laboratory within the pharmacy curriculum.  
Most importantly the pharmacy students needed to have 
progressed to a point of full understanding of a drug (i.e. – 
therapeutic uses, mechanism of action, and metabolism) that 
has PGt considerations.  Additionally, the laboratory should be 
part of the requisite curriculum, given that PGt is a required 
component of the pharmacy curriculum per the ACPE 
Standards 2016.2  Therefore the IPE laboratory was housed in 
the required pharmacy practice laboratory that coincides with 
a didactic integrated cardiovascular module.  In the didactic 
course the antiplatelet drugs are taught, including clopidogrel 
(Plavix®), an ideal choice for considering a drug-gene 
interaction. 
The IPE laboratory was also a mandatory component of the PA 
curriculum.  The Master of Science in Physician Assistant 
Studies is a 27-month program, and this laboratory fell within 
the 18th month of the program.  At the time of the laboratory, 
the PA students had studied antiplatelet therapy, but had not 
been introduced to PGt.  The pre-laboratory knowledge base 
of each of the student cohorts, pharmacy and PA, may 
accurately reflect the current status of healthcare teams in 
clinical practice, which is ideal for the experience. 
 
The laboratory was an hour-long session and consisted of a 
presentation on the use of buccal swabs to obtain DNA, PCR 
amplification of target genes, and interpretation of PGt testing 
results.   Following the presentation, teams comprised of 3-4 
pharmacy students and 1-2 PA students were provided unique 
patient cases.  The patient cases, developed in collaboration 
with a pharmacy practice faculty member, provided a scenario 
in which antiplatelet therapy would be recommended.  Each 
of the patient cases also provided the CYP2C19 genotype of 
the patient.  Appendix A provides an example patient case.  
Following discussion of the case, the interprofessional teams 
provided a recommendation for antiplatelet therapy based 
the CPIC guidelines for the clopidogrel-CYP2C19 drug-gene 
interaction.6 
 
Students from both disciplines were surveyed prior to and 
following the laboratory.  The number of pharmacy students 
and PA students that participated in the survey were 71 and 
25, respectively.  The survey used a 0-5 point Likert scale, 
where 0 equates to “not confident”, 3 is “somewhat 
confident”, and 5 is “very confident.” 7  The survey consisted 
of 12 questions focused on student confidence in 
understanding PGt and perceptions about utilizing PGt data in 
an interdisciplinary team to make therapeutic decisions.  The 
survey questions were created using the ACPE Standards 2016 
as a guide and with consideration of the goals for the IPE 
laboratory.  The IPE laboratory is an evolution of previous PGt 
laboratories that were conducted at other institutions.  For 
comparison’s sake, several of the survey questions from the 
previous laboratories were also included.8  Unique to the IPE 
laboratory survey were questions regarding interprofessional 
communication.  The median responses to the pre- and post-
laboratory survey from each student group were analyzed 
using a Wilcoxon signed test in SPSS 22.0, with statistical 
significance designated as p < 0.01.  This study was approved 
by the Manchester University Institutional Review Board. 
 
Student Response 
For every question on the survey, and in both the pharmacy 
and PA student cohorts, the median response significantly 
increased post-laboratory (Table 1).  The questions with the 
largest increase in median Likert response were shared across 
student cohorts, namely “I feel confident in my ability to 
explain pharmacogenetic data to other members of an 
interprofessional team,” “I feel confident in my ability to 
interpret pharmacogenetic data, and “I feel confident in my 
ability to recommend prescriptions or dosages for certain 
drugs based on pharmacogenetic data.”  In general, the 
difference between the pre- and post-laboratory responses 
was greater for the PA students than the pharmacy students.  
Overall, the increase in the median Likert responses indicates 
that students’ confidence in understanding and ability to 
explain PGt improved during the hour-long IPE laboratory. 
 
In addition to survey data, several observations were made by 
the IPE laboratory designers.  One is that the pharmacy and 
PA students worked well in the interprofessional teams.  Most 
of the teams quickly established a team approach, in that 
groups were eager to converse about the patient cases and 
representation and input was equally divided among the 
professions.  Given that the PA students had less PGt 
background knowledge, this was especially positive to 
observe.  In addition, the laboratory designers noted that 
while both pharmacy and PA students consulted and utilized 
the CPIC guidelines, each profession brought a unique 
perspective to the discussion of the patient case.  For 
example, the pharmacy students noted the cost of the 
alternative therapies that are indicated by the CPIC guidelines, 
and began a debate about cost versus best practices.  The PA 
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students remarked on the protocol for changing therapies in 
patients, and the interprofessional teams worked together to 
find correct protocols for changing antiplatelet therapies.  
Overall, the students engaged in authentic interprofessional 
interactions, participated in peer-peer teaching, and shared 
conflicting viewpoints collegially.  
 
Development of Case Themes 
There are two themes in this work.  First, the interpretation 
and clinical application of PGt data was a focus of the 
education and evaluation.  Second, this work stressed the 
importance of utilizing team members’ strengths to educate 
each other and treat patients in the best manner possible.  
Both themes are crucial in pharmacy education, and are 
mandated to be included in pharmacy curricula by the ACPE 
Standards 2016.  This report describes the first documented 
intersection of PGt and IPE in pharmacy education. 
 
There is little guidance from educational governing bodies with 
respect to the depth and breadth of PGt education necessary.  
There are several potential pedagogies to teach PGt, although 
recent evidence suggests that laboratory exercises centered in 
PGt provide invaluable opportunities for connecting the science 
of PGt to clinical application.8-10  Previous literature reports 
have described PGt centered laboratories in which pharmacy 
students provide samples and participate, in various degrees, 
in the genotyping procedure.8, 11, 12  Each of these reports 
confirm that student understanding of genetic sample 
procurement and genotyping and comprehension of PGt 
principles increased following the laboratory.  In this PGt 
centered laboratory, genotyping of the laboratory participants 
did not occur; instead the process of genotyping was described 
with a short presentation.  Both pharmacy and PA students, 
reported an enhanced understanding of genetic sample 
procurement and genotyping following the laboratory.  Herein 
lies a difficult uncertainty.  All of the student groups reported 
an improved understanding of PGt principles, yet it is 
impossible to speculate and compare the extent of each 
student group’s PGt knowledge.  Furthermore, what extent of 
PGt education is necessary in pharmacy education?  Recall that 
most pharmacists will not conduct actual genotyping 
procedures, but will play a critical role in interpreting potential 
drug-gene interactions and explanation of drug-gene 
interactions to patients and other healthcare providers.4  While 
the novelty of genotyping laboratory participants is exciting 
and may generate heightened student engagement, it may be 
an unnecessary expense given that similar outcomes were 
achieved without genotyping participants.   Of course, inclusion 
of genotyping depends on the goals of the educational 
experience.  Perhaps future PGt centered laboratories should 
focus on training pharmacists in data interpretation and 
explanation of clinical results to standardized patients or other 
healthcare providers, in order to more accurately reflect real 
world scenarios. 
 
Introducing PGt as an IPE experience is novel.  Previous IPE 
laboratories within pharmacy education have focused on a 
myriad of topics (e.g. – pediatric prescribing, patient safety, 
diabetes care, and social and health-related issues to caring 
for the elderly, etc.).13-16  These laboratories have successfully 
demonstrated that perceptions of interprofessional 
collaboration are improved and comfort level with other 
healthcare providers increased.17  The survey data collected 
from the IPE PGt laboratory supports other IPE laboratory 
findings.  In particular, the survey questions regarding 
confidence in the ability to explain best practices for collecting 
samples to other healthcare professionals and the ability to 
explain pharmacogenetic data to other members of an 
interprofessional team had large increases on the Likert scale 
post-laboratory.  Similar to other topics that have been 
covered in IPE laboratories, PGt is a defined niche.  A niche 
that lends itself nicely to IPE experiences because it can be 
introduced and explored by students quickly, it engages 
several healthcare professions, and PGt will play a role in the 
practitioners’ careers.  Engaging the pharmacy and PA 
students in the IPE experience will prepare students to be 
practice- and team-ready.  The IPE laboratory also 
demonstrated to both pharmacy and PA students the 
members on an interprofessional team that could provide 
assistance or guidance in analyzing and utilizing PGt in the 
clinical setting. 
 
Based on the survey and observational data from the IPE PGt 
experience, students became engaged in the subject matter, 
became more comfortable with PGt knowledge and sharing of 
that knowledge, and worked well in their interprofessional 
teams.  The Manchester University Student Personalized 
Medicine Coalition noted that experiences like this laboratory 
could reduce any barriers that healthcare professionals may 
have with regards to PGt knowledge and application.18, 19 
 
Exploration of Case Impact 
This one-hour interdisciplinary laboratory is a simple, cost-
effective, and nonthreatening way to introduce healthcare 
students to PGx.  This IPE experience demonstrates that 
within the confines of a one-hour laboratory, students can 
become more confident in their abilities to understand, 
utilize, and discuss PGt data.  To the authors’ knowledge, this 
is the first use of IPE to explore PGt in pharmacy education, 
and given the success of the laboratory, implementation of 
similar laboratories in pharmacy curricula is recommended. 
 
The laboratory can be easily adapted into various 
circumstances.  Given that the laboratory consisted of a 
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PowerPoint presentation and case discussions, it could easily 
be adapted to an online format.  In this way programs that are 
not co-located could easily participate and proximity no 
longer becomes a requirement for the experience.  
Additionally, the clopidogrel-CYP2C19 drug-gene interaction 
was featured in this laboratory because it is a simple PGt 
interaction and CPIC guidelines exist for the interaction, 
although several other drug-gene interaction examples exist 
and could be utilized as well.20   
 
One challenge the designers faced was partnering with other 
professional programs to create the IPE experience.  Given 
that Manchester University has only one professional degree 
program, the organization and logistics for partnering with 
other local professional programs required prospective 
planning.  Although, given one successful completion of the 
laboratory, several other professional programs are now 
interested in participating.  The designers suggest utilizing this 
publication to demonstrate the ease, accessibility, and 
attained objectives of the IPE PGt experience.   
 
As discussed earlier, several PGt laboratories in pharmacy 
education feature a genotyping exercise in which students are 
genotyped.  While the IPE PGt laboratory successfully 
achieved the designer’s objectives for the laboratory, 
genotyping may further ensure student engagement in 
pharmacogenetic exercises.  The added cost for genotyping 
~100 students would be approximately three hundred US 
dollars.  Recent advances in our own research laboratories will 
allow us to genotype the pharmacy and PA students within 
sixty minutes of DNA extraction, so that the students will be 
provided the genotypes during the laboratory period.  In the 
next iteration of the IPE PGt laboratory, students will be 
genotyped for CYP2C19*2, the most common loss-of-function 
single nucleotide polymorphism (SNP) for CYP2C19.  To date, 
there have been no publications on including multiple 
disciplines in this experience, and it will be interesting to 
compare the student 2016 survey results with that of the 
2015 laboratory where genotyping was not included.  
Providing students’ genotypes may enhance student interest 
and participation in the laboratory and in the subject matter, 
although if no differences are observed between the 2015 and 
2016 laboratories, then inclusion of the genotyping 
component may be an unnecessary expense, as previously 
noted. 
 
Several minor adjustments will also be made in the future 
laboratory.  For instance, pre-laboratory work will be assigned 
to all of the students.  The pre-laboratory work will consist of 
a video focusing on sample acquisition, processing and data 
interpretation followed by an assessment to determine 
student learning from the video.  The purpose of the pre-
laboratory work is to create a similar knowledge base for all of 
the students and to generate extra time in class for case-
based discussion and presentation.   In addition, the sample 
acquisition portion of the pre-laboratory video will include a 
description of several methods to obtain DNA samples.  
Several students noted that only one method for sample 
collection was demonstrated and that discussion on other 
methods may increase their confidence with regards to 
sample collection for pharmacogenetic analysis.  Also, 
additional patient cases will be added to the interdisciplinary 
laboratory, so that both pharmacy and PA students can 
explore the guidelines in greater detail and generate further 
discussion about PGt. 
 
The one-hour IPE laboratory successfully engaged pharmacy 
and PA students in discussions about PGt and increased the 
students’ confidence in understanding and utilizing PGt in 
clinical decision-making.  Given their experiences from this 
laboratory, students may be more confident in utilizing PGt 
data for clinical decision making in practice settings.  In 
addition, the exercise may have reduced the possible 
intimidation by PGt data and application, when it inevitability 
is incorporated as a standard of care.  Given that the vast 
majority of the students found the exercise to be relevant to 
their curriculum, the laboratory will continue to be a part of 
both professional programs with the minor modifications 
noted above.  An IPE PGt laboratory experience can aid in 
successfully preparing practitioners for the future of precision 
medicine.   
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a0: not confident, 3: somewhat confident, 5: very confident, bIQR: interquartile range,*comparison between pre-and post- 
laboratory aggregate survey data for each discipline, statistical significance with p < 0.01. 
 
 
Appendix A – Example of a Patient Case used in the IPE PGt laboratory 
SR is a 54 year old male with a history of NSTEMI 6 months ago with placement of a drug eluting stent. He presents to the hospital 
with recurrent angina and EKG findings and laboratory data are consistent with a new NSTEMI. He is currently receiving both 
clopidogrel and aspirin to prevent stent thrombosis. The physician is concerned about the potential that SR isn’t responding well to 
clopidogrel and is obtaining genetic data to help guide future therapy.  Genotyping results reveal that SR’s CYP2C19 genotype is 
*2/*2.  Recommend therapy for SR 
 
Table 1: Pre- and post-interprofessional laboratory survey results   
 Pharmacy Students (N = 71) Physician Assistants Students (N = 25) 
 Pre Lab Post Lab Pre Lab Post Lab 
Indicate your agreement with the 
following statementsa: 
 
Median (IQRb) Median (IQRb) Median (IQRb) Median (IQRb) 
I feel confident in my ability to describe the 
concept of a prodrug and metabolism to an 
active drug. 
3 (3-4) 4 (4-5)* 2 (1-3.5) 4 (3-4)* 
I feel confident in my ability to explain and 
understand the concepts of genetic 
variation and polymorphisms. 
3 (2-3) 4 (3-4)* 3 (0.5-3) 4 (3-4)* 
I feel confident in my ability to describe 
pharmacogenetics and pharmacogenomics. 
3 (1-3) 3 (3-4)* 1 (0-2.5) 3 (2.5-4)* 
I feel confident in my ability to employ best 
practices for collecting samples for 
pharmacogenetic analysis. 
2 (1-3) 3 (3-4)* 1 (0-1) 3 (1.25-4)* 
I feel confident in my ability to describe the 
basic process of genetic sampling and how 
genotyping is performed. 
2 (1-3) 3 (3-4)* 1 (1-2) 3 (2.5-4)* 
I feel confident in my ability to interpret 
pharmacogenetic data. 
2 (1-2) 3 (3-4)* 1 (0-1) 3 (2-4)* 
I feel confident in my ability to recommend 
prescriptions or dosages for certain drugs 
based on pharmacogenetics data. 
2 (1-3) 4 (3-4)* 1 (0-2) 4 (3-4)* 
I feel confident in my ability to utilize CPIC 
guidelines. 
0 (0-2) 4 (3-4)* 0 (0-0) 3 (1.5-4)* 
I feel confident in my ability to explain best 
practices for collecting samples for 
pharmacogenetic analysis to other 
healthcare professionals. 
1 (0-2) 3 (3-4)* 1 (0-1) 3 (1.5-4)* 
I feel confident in my ability to explain 
pharmacogenetic data to other members of 
an interprofessional team. 
1 (0-2) 3 (3-4)* 0 (0-3) 4 (2.5-4)* 
I feel confident in my ability to provide 
rationale for performing genotyping. 
2 (0-3) 4 (3-4)* 1 (0-3) 4 (3-4)* 
This exercise is relevant in the healthcare 
curriculum. 
4 (3-5) 5 (4-5)* 2 (0-4) 4 (3-5)* 
